Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Zhejiang AngLiKang Pharmaceutical Co., Ltd. specializes in the development and manufacturing of generic and specialty pharmaceuticals, primarily focusing on the Chinese market. The company's competitive edge lies in its robust R&D capabilities and a diverse product portfolio, which includes over 100 generic drugs across various therapeutic areas.
Zhejiang AngLiKang generates revenue primarily through the sale of generic drugs, leveraging its strong R&D to produce cost-effective alternatives to branded medications. The company benefits from economies of scale in production and has established a solid distribution network across China, which enhances its pricing power.
Regulatory approvals for new generic drugs
Market share gains in the Chinese pharmaceutical sector
Changes in pricing regulations affecting generic drugs
Partnerships or collaborations with larger pharmaceutical companies
Regulatory changes in drug approval processes
Intellectual property challenges from branded competitors
Increased competition from domestic and international generic manufacturers
Potential price erosion due to aggressive pricing strategies by competitors
Moderate debt levels could impact financial flexibility if market conditions worsen
Potential liquidity risks if cash flow generation does not improve
moderate - as a pharmaceutical company, demand for its products is relatively inelastic, but economic downturns can impact overall healthcare spending.
Low - the company's operations are not heavily reliant on debt financing, and interest rate changes have minimal impact on its cost structure.
minimal - the company has a manageable debt-to-equity ratio of 0.46, indicating low reliance on external financing.
growth - investors may be drawn to the company's potential for revenue growth through new product launches and market expansion.
moderate - historical volatility is in line with industry peers, reflecting both growth potential and regulatory risks.
